Co-authored by Seethamraju, the study reported that five of the ten patients treated with leronlimab survived. The study also described the drug as “a novel approach” to resolving unchecked inflammation.



Based on the positive results with those patients, the FDA approved Seethamraju’s application for a phase 2 trial of leronlimab. That trial began enrolling both inpatients and outpatients with mild-to-moderate COVID-19 on April 2. A total of 75 are participating in this latest phase.